Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Cytoclonal Pharmaceutics (NasdaqNM:CYPH)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Location
2110 Research Row, Suite 621
Dallas, TX 75235
Phone: (214) 353-2922
Fax: (214) 350-9514
Email: info@cytoclonal.com
Employees (last reported count): 34
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 21%
·Over the last 6 months:
 · one insider buy; 100.0K shares (2.4% of insider shares)
 · 3 insider sells; 938.0K shares
  (22.3% of insider shares)
·Institutional: 4% (5% of float)
(17 institutions)
·Net Inst. Selling: 133.0K shares (+26.39%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Cytoclonal Pharmaceutics Inc. is a biopharmaceutical drug development company specializing in therapeutic products for human diseases with an emphasis on the treatment and prevention of cancer and infectious diseases. To date, the Company has been involved solely in research and development activities relating to several proprietary products and technologies that are at various stages of development. These include Paclitaxal, the active ingredient in Taxol, the anti-cancer agent marketed by Bristol-Myers Squibb. The Company also has two drug design platform technologies: Quantum Core Technologies (QCT) and OASIS. QCT is a computer-assisted drug design technology platform, primarily targeted to inhibition of proteins involved in disease. OASIS is its antisense library of reagents for regulating genes involved in disease.
More from Market Guide: Expanded Business Description

Financial Summary
CYPH, a development stage biopharmaceutical company, focuses on the development of diagnostic and therapeutic products for the identification, treatment, and prevention of cancer and infectious diseases. For the three months ended 3/31/01, revenues fell 3% to $333 thousand. Net loss applicable to Common fell 38% to $1.5 million. Results reflect reduced amounts earned under the agreement with Bristol-Myers Squibb, offset by lower public and financial relations expenses.

Recent Earnings Announcement
For the 3 months ended 06/30/2001, revenues were 334; after tax earnings were -2,949. (Preliminary; reported in thousands of dollars.)

More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Gary Frashier, 64
Chairman
--  
Ronald Goode, Ph.D., 57
Pres, CEO
--  
Arthur Bollon, Ph.D., 58
Vice Chairman
$227K
Dorit Arad, Ph.D., 48
Exec. VP of Drug Design
132K
Joan Gillett, 51
VP, Controller, and Principal Accounting Officer
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CYPHAs of 31-Aug-2001
Price and Volume
52-Week Low
on 13-Mar-2001
$2.656
Recent Price$3.50 
52-Week High
on 1-Sep-2000
$10.00 
Beta0.83 
Daily Volume (3-month avg)40.7K
Daily Volume (10-day avg)38.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-62.4%
52-Week Change
relative to S&P500
-49.6%
Share-Related Items
Market Capitalization$56.6M
Shares Outstanding16.2M
Float12.8M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq*)$2.08 
Earnings (ttm)-$0.49 
Earnings (mrq)-$0.18 
Sales (ttm)$0.05 
Cash (mrq*)$2.09 
Valuation Ratios
Price/Book (mrq*)1.68 
Price/EarningsN/A 
Price/Sales (ttm)67.57 
Income Statements
Sales (ttm)$845.0K
EBITDA (ttm*)-$7.57M
Income available to common (ttm)-$8.01M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter
(fully updated)
31-Mar-2001
Most recent quarter
(flash earnings)
30-June-2001
Management Effectiveness
Return on Assets (ttm)-20.41%
Return on Equity (ttm)-22.18%
Financial Strength
Current Ratio (mrq*)24.01 
Debt/Equity (mrq*)0 
Total Cash (mrq)$0 
Short Interest
As of 8-Aug-2001
Shares Short443.0K
Percent of Float3.5%
Shares Short
(Prior Month)
491.0K
Short Ratio8.52 
Daily Volume52.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001, except mrq*/ttm* items as of 31-Mar-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.